Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Licensing Agreements 12
Kite Pharma to Enter into Licensing Agreement with Sangamo Therapeutics 12
Sangamo Therapeutics Enters into Licensing Agreement with Pfizer 14
Pfizer Enters into Licensing Agreement with Sangamo Therapeutics 15
Biogen Idec Enters into Licensing Agreement with Sangamo BioSciences for Hemoglobinopathies Therapeutics 16
Shire Amends Licensing Agreement with Sangamo BioSciences for ZFP Therapeutics 17
Sangamo BioSciences Enters into Licensing Agreement for mRNA Delivery Technology 19
Equity Offering 20
Sangamo Therapeutics Raises USD230 Million in Public Offering of Shares 20
Sangamo BioSciences Raises USD72.5 Million in Public Offering of Shares 22
Sangamo Therapeutics Raises USD83.4 Million in Public Offering of Shares 24
Sangamo BioSciences Completes Public Offering Of Shares For US$100 Million 26
Sangamo BioSciences Completes Public Offering Of Shares For US$74.2 Million 28
Asset Transactions 30
Bioverativ to Acquire Rights to Genome Editing Program from Sangamo BioSciences 30
Acquisition 31
Sangamo Therapeutics Acquires TxCell 31
Sangamo BioSciences Completes Acquisition Of Ceregene, Biotechnology Company 33
Sangamo Therapeutics Inc – Key Competitors 35
Sangamo Therapeutics Inc – Key Employees 36
Sangamo Therapeutics Inc – Locations And Subsidiaries 37
Head Office 37
Other Locations & Subsidiaries 37
Recent Developments 38
Strategy And Business Planning 38
Nov 09, 2017: Sangamo Announces Plans For New Headquarters In Brisbane, California 38
Financial Announcements 39
Aug 08, 2018: Sangamo Therapeutics reports second quarter 2018 financial results 39
May 08, 2018: Sangamo Therapeutics Reports First Quarter 2018 Financial Results 41
Feb 21, 2018: Sangamo Therapeutics Reports Fourth Quarter And Full Year 2017 Financial Results 43
Nov 09, 2017: Sangamo Therapeutics Reports Third Quarter 2017 Financial Results 45
Aug 09, 2017: Sangamo Therapeutics Reports Second Quarter 2017 Financial Results 47
May 10, 2017: Sangamo Therapeutics Reports First Quarter 2017 Financial Results 49
Feb 28, 2017: Sangamo Therapeutics Reports Fourth Quarter And Full Year 2016 Financial Results 50
Feb 27, 2017: Sangamo Therapeutics Announces Chief Financial Officer Succession 52
Corporate Communications 53
Jun 28, 2018: Sangamo Therapeutics Appoints Karen Smith to its Board of Directors 53
May 03, 2018: Sangamo Therapeutics Announces Senior Leadership Changes 54
Feb 12, 2018: Sangamo Therapeutics Appoints Heather D. Turner As Senior Vice President And General Counsel 55
Jun 29, 2017: Sangamo Therapeutics Appoints Roger Jeffs, Ph.D. and Joseph S. Zakrzewski to its Board of Directors 56
Apr 25, 2017: Sangamo Announces The Retirement Of Its Founder And Genome Editing Pioneer Edward Lanphier From The Board Of Directors 57
Legal and Regulatory 58
Aug 23, 2018: SEC Charges Former Pharma Executive and Others with Insider Trading 58
Government and Public Interest 59
Apr 27, 2018: Therapies Targeting Cancer, Deadly Immune Disorder and Life-Threatening Blood Condition Get Almost $32 Million Boost from Stem Cell Agency 59
Product News 61
11/01/2017: Bioverativ to Present New Data on ST-400 at ASH 2017 Annual Meeting 61
10/17/2017: Sangamo Therapeutics Announces Presentations At 2017 Annual Congress Of The European Society Of Gene And Cell Therapy 62
08/25/2017: Sangamo And Pfizer Announce First Patient Receives Treatment In Phase 1/2 Clinical Trial Evaluating SB-525 Investigational Gene Therapy For Hemophilia A 63
04/27/2018: Sangamo Announces $8 Million CIRM Grant For ST-400 — A Gene-Edited Cell Therapy Candidate — To Treat Transfusion-Dependent Beta-Thalassemia 64
Product Approvals 65
Oct 02, 2017: Sangamo And Bioverativ Announce FDA Acceptance of IND Application For ST-400 – A Gene-Edited Cell Therapy Candidate – to Treat Beta-Thalassemia 65
Jun 07, 2017: Sangamo Therapeutics And Pfizer Announce That SB-525 Investigational Hemophilia A Gene Therapy Receives Orphan Medicinal Product Designation From The European Medicines Agency 66
May 16, 2017: Sangamo Receives Fast Track Designation From The FDA For SB-525 Investigational Hemophilia A Gene Therapy 67
May 04, 2017: Sangamo Therapeutics Announces Orphan Drug Designation for SB-525 cDNA Gene Therapy for Hemophilia A 68
Feb 27, 2017: Sangamo Therapeutics Receives Rare Pediatric Disease Designation From FDA For SB-318 In Vivo Genome Editing Therapeutic For MPS I 69
Jan 11, 2017: Sangamo Therapeutics Receives Orphan Drug Designation from the FDA for SB-318 Genome Editing Treatment for MPS I 70
Jan 05, 2017: Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For SB-525 Gene Therapy Program For Hemophilia A 71
Clinical Trials 72
Feb 08, 2017: Sangamo Therapeutics Announces Data on SB-318 at The 13th Annual WORLDSymposium Meeting 72
Feb 08, 2017: Sangamo Therapeutics Announces Data on SB-913 at The 13th Annual WORLDSymposium Meeting 73
Other Significant Developments 74
Jan 06, 2017: Sangamo BioSciences Changes Name To Sangamo Therapeutics, Underscoring Focus On Clinical Development Of Genomic Therapies 74
Appendix 75
Methodology 75
About GlobalData 75
Contact Us 75
Disclaimer 75
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sangamo Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Kite Pharma to Enter into Licensing Agreement with Sangamo Therapeutics 12
Sangamo Therapeutics Enters into Licensing Agreement with Pfizer 14
Pfizer Enters into Licensing Agreement with Sangamo Therapeutics 15
Biogen Idec Enters into Licensing Agreement with Sangamo BioSciences for Hemoglobinopathies Therapeutics 16
Shire Amends Licensing Agreement with Sangamo BioSciences for ZFP Therapeutics 17
Sangamo BioSciences Enters into Licensing Agreement for mRNA Delivery Technology 19
Sangamo Therapeutics Raises USD230 Million in Public Offering of Shares 20
Sangamo BioSciences Raises USD72.5 Million in Public Offering of Shares 22
Sangamo Therapeutics Raises USD83.4 Million in Public Offering of Shares 24
Sangamo BioSciences Completes Public Offering Of Shares For US$100 Million 26
Sangamo BioSciences Completes Public Offering Of Shares For US$74.2 Million 28
Bioverativ to Acquire Rights to Genome Editing Program from Sangamo BioSciences 30
Sangamo Therapeutics Acquires TxCell 31
Sangamo BioSciences Completes Acquisition Of Ceregene, Biotechnology Company 33
Sangamo Therapeutics Inc, Key Competitors 35
Sangamo Therapeutics Inc, Key Employees 36
Sangamo Therapeutics Inc, Subsidiaries 37
List of Figures
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9